Abstract
The misfolding mutant Huntingtin protein (HTT) has been identified as the primary trigger of dysregulation and degeneration in Huntington’s disease (HD). In order to counteract the abnormal protein–protein interactions and aggregation that characterize this and related protein misfolding diseases, antibody fragments that bind near the pathogenic region have been identified and characterized, and then engineered for improved affinity, intracellular solubility, and bispecific function. HD is a paradigm disease for misfolding proteins, since the readouts are exceptionally robust in cell and animal models. Candidate antibody fragments include single-chain Fv (scFv) and single domain antibodies (dAb, VL, VH). They have been selected from phage display libraries, or cloned from monoclonal antibodies of known specificity for the HTT Exon1 targets.
Preclinical immunotherapies have been tested with gene delivery via transgenes, or delivered using AAV or lentiviral gene therapy vectors. These intrabodies can strongly affect the HD phenotype across a range of epitopes and model systems. Given that individuals with HD can be identified genetically in a premanifest stage of disease, the potential for immunotherapeutic interventions is very promising.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Wexler NS, Rose EA, Housman DE (1991) Molecular approaches to hereditary diseases of the nervous system: Huntington’s disease as a paradigm. Annu Rev Neurosci 14:503–529
Crook ZR, Housman D (2011) Huntington’s disease: can mice lead the way to treatment? Neuron 69(3):423–435
Gonitel R, Moffitt H, Sathasivam K, Woodman B, Detloff PJ, Faull RL et al (2008) DNA instability in postmitotic neurons. Proc Natl Acad Sci U S A 105(9):3467–3472
Lecerf JM, Shirley TL, Zhu Q, Kazantsev A, Amersdorfer P, Housman DE et al (2001) Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington’s disease. Proc Natl Acad Sci U S A 98(8):4764–4769
Ehrlich ME, Conti L, Toselli M, Taglietti L, Fiorillo E, Taglietti V et al (2001) ST14A cells have properties of a medium-size spiny neuron. Exp Neurol 167(2):215–226
Kvam E, Nannenga BL, Wang MS, Jia Z, Sierks MR, Messer A (2009) Conformational targeting of fibrillar polyglutamine proteins in live cells escalates aggregation and cytotoxicity. PLoS One 4(5):e5727
Miller TW, Messer A (2005) Intrabody applications in neurological disorders: progress and future prospects. Mol Ther 12(3):394–401
Murphy RC, Messer A (2004) A single-chain Fv intrabody provides functional protection against the effects of mutant protein in an organotypic slice culture model of Huntington’s disease. Brain Res Mol Brain Res 121(1-2):141–145
Steffan JS, Agrawal N, Pallos J, Rockabrand E, Trotman LC, Slepko N et al (2004) SUMO modification of Huntingtin and Huntington’s disease pathology. Science 304(5667):100–104
Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C et al (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87(3):493–506
Gray M, Shirasaki DI, Cepeda C, Andre VM, Wilburn B, Lu XH et al (2008) Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J Neurosci 28(24):6182–6195
Slow EJ, van Raamsdonk J, Rogers D, Coleman SH, Graham RK, Deng Y et al (2003) Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet 12(13):1555–1567
Miller TW, Shirley TL, Wolfgang WJ, Kang X, Messer A (2003) DNA vaccination against mutant huntingtin ameliorates the HDR6/2 diabetic phenotype. Mol Ther 7(5 Pt 1):572–579
Wheeler VC, Gutekunst CA, Vrbanac V, Lebel LA, Schilling G, Hersch S et al (2002) Early phenotypes that presage late-onset neurodegenerative disease allow testing of modifiers in Hdh CAG knock-in mice. Hum Mol Genet 11(6):633–640
Menalled LB, Sison JD, Dragatsis I, Zeitlin S, Chesselet MF (2003) Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington’s disease with 140 CAG repeats. J Comp Neurol 465(1):11–26
Kvam E, Sierks MR, Shoemaker CB, Messer A (2010) Physico-chemical determinants of soluble intrabody expression in mammalian cell cytoplasm. Protein Eng Des Sel 23(6):489–498
Miller TW, Zhou C, Gines S, MacDonald ME, Mazarakis ND, Bates GP et al (2005) A human single-chain Fv intrabody preferentially targets amino-terminal Huntingtin’s fragments in striatal models of Huntington’s disease. Neurobiol Dis 19(1-2):47–56
Wolfgang WJ, Miller TW, Webster JM, Huston JS, Thompson LM, Marsh JL et al (2005) Suppression of Huntington’s disease pathology in Drosophila by human single-chain Fv antibodies. Proc Natl Acad Sci U S A 102(32):11563–11568
Dragatsis I, Levine MS, Zeitlin S (2000) Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat Genet 26(3):300–306
Bortvedt SF, McLear JA, Messer A, Ahern-Rindell AJ, Wolfgang WJ (2010) Cystamine and intrabody co-treatment confers additional benefits in a fly model of Huntington’s disease. Neurobiol Dis 40(1):130–134
Hathorn T, Snyder-Keller A, Messer A (2011) Nicotinamide improves motor deficits and upregulates PGC-1alpha and BDNF gene expression in a mouse model of Huntington’s disease. Neurobiol Dis 41(1):43–50
Snyder-Keller A, McLear JA, Hathorn T, Messer A (2010) Early or late-stage anti-N-terminal Huntingtin intrabody gene therapy reduces pathological features in B6.HDR6/1 mice. J Neuropathol Exp Neurol 69(10):1078–1085
Colby DW, Garg P, Holden T, Chao G, Webster JM, Messer A et al (2004) Development of a human light chain variable domain (V(L)) intracellular antibody specific for the amino terminus of huntingtin via yeast surface display. J Mol Biol 342(3):901–912
Colby DW, Chu Y, Cassady JP, Duennwald M, Zazulak H, Webster JM et al (2004) Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody. Proc Natl Acad Sci U S A 101(51):17616–17621
Southwell AL, Ko J, Patterson PH (2009) Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington’s disease. J Neurosci 29(43):13589–13602
Southwell AL, Khoshnan A, Dunn DE, Bugg CW, Lo DC, Patterson PH (2008) Intrabodies binding the proline-rich domains of mutant huntingtin increase its turnover and reduce neurotoxicity. J Neurosci 28(36):9013–9020
Butler DC, Snyder-Keller A, De Genst E, Messer A (2014) Differential nuclear localization of complexes may underlie in vivo intrabody efficacy in Huntington’s disease. Protein Eng Des Sel 27(10):359–363
Rockabrand E, Slepko N, Pantalone A, Nukala VN, Kazantsev A, Marsh JL et al (2007) The first 17 amino acids of Huntingtin modulate its sub-cellular localization, aggregation and effects on calcium homeostasis. Hum Mol Genet 16(1):61–77
Qin ZH, Wang Y, Sapp E, Cuiffo B, Wanker E, Hayden MR et al (2004) Huntingtin bodies sequester vesicle-associated proteins by a polyproline-dependent interaction. J Neurosci 24(1):269–281
Ko J, Ou S, Patterson PH (2001) New anti-huntingtin monoclonal antibodies: implications for huntingtin conformation and its binding proteins. Brain Res Bull 56(3-4):319–329
Khoshnan A, Ko J, Patterson PH (2002) Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity. Proc Natl Acad Sci U S A 99(2):1002–1007
Southwell AL, Bugg CW, Kaltenbach LS, Dunn D, Butland S, Weiss A et al (2011) Perturbation with intrabodies reveals that calpain cleavage is required for degradation of huntingtin exon 1. PLoS One 6(1):e16676
Smith DL, Portier R, Woodman B, Hockly E, Mahal A, Klunk WE et al (2001) Inhibition of polyglutamine aggregation in R6/2 HD brain slices-complex dose-response profiles. Neurobiol Dis 8(6):1017–1026
Wang CE, Zhou H, McGuire JR, Cerullo V, Lee B, Li SH et al (2008) Suppression of neuropil aggregates and neurological symptoms by an intracellular antibody implicates the cytoplasmic toxicity of mutant huntingtin. J Cell Biol 181(5):803–816
Rechsteiner M, Rogers SW (1996) PEST sequences and regulation by proteolysis. Trends Biochem Sci 21(7):267–271
Butler DC, Messer A (2011) Bifunctional anti-huntingtin proteasome-directed intrabodies mediate efficient degradation of mutant huntingtin exon 1 protein fragments. PLoS One 6(12):e29199
Verhoef LG, Lindsten K, Masucci MG, Dantuma NP (2002) Aggregate formation inhibits proteasomal degradation of polyglutamine proteins. Hum Mol Genet 11(22):2689–2700
Ravikumar B, Duden R, Rubinsztein DC (2002) Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. Hum Mol Genet 11(9):1107–1117
Rose C, Menzies FM, Renna M, Acevedo-Arozena A, Corrochano S, Sadiq O et al (2010) Rilmenidine attenuates toxicity of polyglutamine expansions in a mouse model of Huntington’s disease. Hum Mol Genet 19(11):2144–2153
Sarkar S, Rubinsztein DC (2008) Huntington’s disease: degradation of mutant huntingtin by autophagy. FEBS J 275(17):4263–4270
Bauer PO, Goswami A, Wong HK, Okuno M, Kurosawa M, Yamada M et al (2010) Harnessing chaperone-mediated autophagy for the selective degradation of mutant huntingtin protein. Nat Biotechnol 28(3):256–263
Spencer B, Emadi S, Desplats P, Eleuteri S, Michael S, Kosberg K et al (2014) ESCRT mediated uptake and degradation of brain targeted alpha-synuclein-single chain antibody attenuates neuronal degeneration in vivo. Mol Ther 22(10):1753–1767
Messer A (2014) Engineered antibody therapies coming of age for aging brains. Mol Ther 22(10):1725–1727
Kwan W, Trager U, Davalos D, Chou A, Bouchard J, Andre R et al (2012) Mutant huntingtin impairs immune cell migration in Huntington disease. J Clin Invest 122(12):4737–4747
Wild E, Magnusson A, Lahiri N, Krus U, Orth M, Tabrizi SJ et al (2011) Abnormal peripheral chemokine profile in Huntington’s disease. PLoS Curr 3:RRN1231
Strand AD, Aragaki AK, Shaw D, Bird T, Holton J, Turner C et al (2005) Gene expression in Huntington’s disease skeletal muscle: a potential biomarker. Hum Mol Genet 14(13):1863–1876
Wood NI, Goodman AO, van der Burg JM, Gazeau V, Brundin P, Bjorkqvist M et al (2008) Increased thirst and drinking in Huntington’s disease and the R6/2 mouse. Brain Res Bull 76(1-2):70–79
Acknowledgments
We thank members of the Messer lab group, especially Drs. David Butler and Abigail Snyder-Keller, and Kevin Manley for helpful discussions of the manuscript. Work in the Messer lab was supported in part by grants from NIH/NINDS NS053912 and NS061257, and NSF REU #DBI1062963; Hereditary Disease Foundation, High Q Foundation/CHDI, Huntington’s Disease Society of America, and the Michael J. Fox Foundation.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media New York
About this protocol
Cite this protocol
Messer, A. (2016). Immunotherapy on Experimental Models for Huntington’s Disease. In: Ingelsson, M., Lannfelt, L. (eds) Immunotherapy and Biomarkers in Neurodegenerative Disorders. Methods in Pharmacology and Toxicology. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-3560-4_10
Download citation
DOI: https://doi.org/10.1007/978-1-4939-3560-4_10
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-3558-1
Online ISBN: 978-1-4939-3560-4
eBook Packages: Springer Protocols